Nicholas von Guionneau is a Senior Analyst at Catalio Capital Management, LP, based in our London office.
His technical expertise is in the field of peripheral nerve regeneration, with a particular focus on pre-clinical development of small protein drug delivery systems, neurotherapeutics and implantable neurodevices. Nicholas currently serves on the Boards of Character Biosciences, LifeSprout Bio, Proto Axiom, Blackrock Neurotech, Boost Neuroscience, and SetPoint Medical.
Prior to Catalio, Nicholas was a Postdoctoral Fellow at Johns Hopkins Medicine, where he developed interventions to improve functional outcomes after peripheral nerve injuries. Before moving into research, he was a clinical doctor at Guy’s and St. Thomas’ NHS Trust in London, UK.
Nicholas earned his MBBS (Bachelor of Medicine, Bachelor of Surgery) degree at Imperial College School of Medicine in London, and his BSc in Medical Sciences (Surgery and Anaesthesia), also from Imperial College London.
